N4 Pharma Non-Executive Director Q&A
Dr Alastair Smith joins as Non-Executive Director; Q&A released on investor hub.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the release of an investor Q&A with Dr Alastair Smith, Non-Executive Director, who recently joined the Board of the Company.
The Q&A is now live on N4 Pharma's interactive investor hub here: https://investors.n4pharma.com/link/mPqEEP
| N4 Pharma plc Nigel Theobald, Chief Executive Officer Luke Cairns, Executive Director Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | Via N4 Pharma Investor Hub Sign up at investors.n4pharma.com https://investors.n4pharma.com/link/VyEJpe |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0) 20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/James Pope | Tel: +44 (0) 20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0) 113 730 3896 |
About N4 Pharma
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform. With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.